Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR-SEQUENCE phase III study in left-sided RAS wild-type metastatic colorectal cancer
2018-000347-60Phase 3Active
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jun 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab, bevacizumab, oxaliplatin, folinic acid, fluorouracil and 1 more in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: 35-month progression-free survival rate. Started Jun 2018; status: active.
02
Drugs
panitumumabbevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-000347-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000347-60.